Premium Only Content

Ivermectin or Molnupiravir For Treating And Killing Covid In Covid Cases Now
There are still many nations where vaccines are not yet widely available,
There is a gradual shift in focus, to antiviral drugs,
Adjunctive chemoprophylaxis
Active treatment of new SARS-CoV-2 infections
Post -vaccination breakthrough COVID-19 cases
The two ways to get new drugs
Develop novel antiviral drugs for SARS-CoV-2
Repurpose existing FDA -approved drugs to treat COVID-19
Ivermectin is the most studied “repurposed” medication globally,
in randomized clinical trials, retrospective studies and meta- analyses.
Molnupiravir and Ivermectin Anti-SARS- CoV-2 Mechanisms, Pharmacokinetics and Pharmacodynamics
Molnupiravir is a broad spectrum antiviral agent against SARS- CoV-2, SARS-CoV,
seasonal or pandemic influenza and MERS corona virus
Ivermectin is an FDA-approved, WHO essential drug used as broad spectrum antiparasitic, antibiotic
and which has demonstrated broad spectrum antiviral activity against RNA viruses, including HIV, Zika, MERS corona virus
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
https://www.sciencedirect.com/science...
5000-fold inhibition of SARS-CoV-2, (99.98% at 48 hours
The inhibitory concentration IC50 of Molnupiravir shows it to be a more potent anti-SARS-CoV-2 agent, compared to Ivermectin in vitro.
Both molnupiravir and ivermectin are well absorbed after oral dosing
Tmax of molnupiravir being 1-1.75 hours,
With a half life of 7 hours
Tmax of ivermectin is 4-6 hours
Very long half life of 81-91 hours
Ivermectin, being lipophilic has a large volume of distribution
Ivermectin has the ability to accumulate in the lungs
The anti-SARS-CoV-2 actions, both of molnupiravir and ivermectin, are dose and concentration dependent
Molnupiravir active metabolite (NHC-5’ Triphosphate), acts as a competitive alternative substrate for viral RNA
causing viral mutagenesis or mutations, which leads to viral error catastrophe and extinction of replication
There is some concern about the safety of NHC -nucleoside triphosphate, which is also mutagenic to mammalian cells
Ivermectin, multifarious actions,
Binding to SARS-CoV-2 spike protein S
Reducing cell entry via human ACE2 receptors
Reducing viral transcription
Inhibition of cytokine production and inflammation
(not yet been shown for molnupiravir)
Complimentary pharmacokinetics and pharmacodynamics of the drugs
May be additive or synergistic
This should be further investigated in anti-SARS- CoV-2 antiviral combination therapy.
A combination of molnupiravir with Ivermectin putatively, in effects on RdRP or cytokine release.
Cost
-
2:32
KJRH
3 years agoOSDH: COVID cases, vaccinations rising
1994 -
2:19
WMAR
4 years agoCOVID cases are surging nationwide
3622 -
9:21:36
Rallied
13 hours ago $3.19 earnedWARZONE CHALLENGES WITH DRDISRESPECT & BOB
86K5 -
7:15:14
SpartakusLIVE
10 hours agoMonday MOTIVATION leaves viewers ENERGIZED and MAXIMIZED to conquer the week
39.2K1 -
3:19:17
Barry Cunningham
9 hours agoPRESIDENT TRUMP IS THE SUM OF THEIR FEARS! IT HAS BEGUN!
66.2K76 -
58:25
Donald Trump Jr.
14 hours agoMike Benz Takes us Inside the Global Censorship Complex | Triggered Ep264
129K128 -
28:36
Scary Mysteries
19 hours agoMISSOURI'S 5 Darkest True Crime Nightmares
25K2 -
3:41:04
LIVE WITH CHRIS'WORLD
14 hours agoLIVE WITH CHRIS’WORLD - Todays News Will Impact Tomorrows Decisions
17.9K4 -
22:24
Jasmin Laine
12 hours agoTrump HUMILIATES Carney: “Too Liberal for Me”—CBS Host GRILLS Him Live
13.2K10 -
1:49:33
Anthony Rogers
14 hours agoThis Stream Will Make You Want to Reinstall FORTNITE
7.74K